Mibenratide

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameMibenratide
Drug Alias Namemibenratide美贝拉肽米苯雷肽mibenratidamibenratidum +[7] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionBeta-1 adrenergic receptor antagonists
TargetsBeta-1 adrenergic receptor
Therapy Area/IndicationsHeart FailureCardiomyopathy, Dilated
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermany
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesJohnson & Johnson
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCorimmun GmbhJanssen Research & Development Llc
Active IndicationsN/A
Inactive IndicationsHeart FailureCardiomyopathy, Dilated

Other Information

ATC CodeN/A
Related LinksN/A